WNT 974

Drug Profile

WNT 974

Alternative Names: LGK-974; NVP-LGK974; WNT-974

Latest Information Update: 17 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novartis
  • Developer Array BioPharma; Novartis Oncology
  • Class Antineoplastics; Pyrazines; Pyridines; Small molecules
  • Mechanism of Action PORCN protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Colorectal cancer
  • Phase I Cancer

Most Recent Events

  • 06 Sep 2017 WNT 974 is still in phase I/II trials for Colorectal cancer (Combination therapy, Metastatic disease) in Belgium, Canada, Israel, Italy, Netherlands, Singapore, Spain and USA (PO) (NCT02278133)
  • 23 Jun 2017 Array BioPharma completes a phase I/II trial in Colorectal cancer (Combination therapy, Metastatic disease) in Spain, Singapore, Netherlands, Italy, Israel, Canada, Belgium, Australia and USA (IV) (NCT02278133)
  • 09 Mar 2017 Novartis reinitiates enrolment in a phase I trial for Cancer (Late stage disease) in USA, Spain and the Netherlands (NCT01351103)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top